Der Lactat-Pyruvat-Quotient im normalen Harn und das pH in den distalen Nierentubuli

Zusammenfassung Der Lactat-Pyruvat-Quoteint im Harn beträgt unter normalen Bedingungen 2,44.

---

Summary The Lactate-Pyruvate ratio of normal urine is 2.44.

     

Über die Wirkung von N-(3′-Phenyl-propyl-(2′))-1,1-diphenyl-propyl-(3)-amin auf den Katecholamin-Stoffwechsel

Zusammenfassung N-(3-Phenyl-propyl-(2))-1,1-diphenyl-propyl-(3)-amin (Segontin®) senkte bei Hunden in einer Dosis von 20 mg/kg s.c. den Noradrenalin-Gehalt in Gehirn, Herz, Gefäßen und Halsganglien um 50–80%.Segontin setzt aus isolierten chromaffinen Granula der Nebenniere der Ratte Adrenalin und Noradrenalin in Freiheit. Die Wirkung ist dosisabhängig und stärker als äquimolare Dosen Tyramin.Diese Katecholaminfreisetzung wird als Ursache der Wirkung von Segontin auf den Katecholamingehalt der Gewebe angesehen.Herrn Dr. FritzLindner zum 60. Geburtstag gewidmet.     

Reciprocal strength ratio in shoulder abduction/adduction in sports and daily living

PURPOSE: Functionally, the shoulder is considered a ball joint, whereby high mobility is attended by low stability. Therefore, muscular balance is decisive for stability. Altered strength ratios are frequently described as "muscular dysbalances" and considered one of the causes of shoulder pathologies, whereby objective quantification is difficult. METHODS: In order to quantify physiological muscle balance, the strength ratio of shoulder abduction/adduction (AB/AD) was determined in 166 untrained men (UM) concentrically at 60 degrees.s-1 (LIDO-Active). The influence on this norm of one-sided (25 high-performance (TPH), 18 leisure tennis players (TPL)) and two-sided athletic exercise (32 gymnasts (GY)), altered daily exercise (11 paraplegics with paralysis time < 4 months (PP), 11 paraplegics with paralysis time > 2 yr (PU)), and a combination of altered daily exercise and athletic activity (16 trained paraplegics (PT)) was examined (ANOVA, alpha = 0.05). RESULTS: Determination of the AB/AD quotient in UM was 0.82. Shoulder stress in sports led to a decrease in quotients compared with UM because of a relatively increased torque in AD (P < 0.01). At the beginning of a paraplegia, the quotient of AB/AD is elevated (P < 0.05). This altered ratio decreases with duration of paralysis (PU) and athletic activity (PT). CONCLUSION: With increased shoulder stress, the altered strength ratios reflect specific requirements of the performance attained. However, the importance of muscular dysbalances for the onset of shoulder complaints must be considered more important than their influence on athletic performance capacity.     

Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6

Oxidative stress and protein aggregation are biochemical hallmarks of Parkinson's disease (PD), a frequent sporadic late-onset degenerative disorder particularly of dopaminergic neurons in the substantia nigra, resulting in impaired spontaneous movement. PARK6 is a rare autosomal-recessively inherited disorder, mimicking the clinical picture of PD with earlier onset and slower progression. Genetic data demonstrated PARK6 to be caused by mutations in the protein PINK1, which is localized to mitochondria and has a serine-threonine kinase domain. To study the effect of PINK1 mutations on oxidative stress, we used primary fibroblasts and immortalized lymphoblasts from three patients homozygous for G309D-PINK1. Oxidative stress was evident from increases in lipid peroxidation and in antioxidant defenses by mitochondrial superoxide dismutase and glutathione. Elevated levels of glutathione reductase and glutathione-S-transferase were also observed. As a putative cause of oxidation, a mild decrease in complex I activity and a trend to superoxide elevation were detectable. These data indicate that PINK1 function is critical to prevent oxidative damage and that peripheral cells may be useful for studies of progression and therapy of PARK6.     

The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients

Besides preventing bleeding episodes, common goals of the treatment of hemophilia include integrating of patients into a normal social life and optimizing their quality of life. Sufficient amounts of factor VIII (FVIII) concentrates, whether recombinant or plasma-derived, are continuously needed. Guidelines for quality assurance of treatment will be a cornerstone to maintain optimal clinical management of patients especially considering financial aspects. Advances in manufacturing technologies have made possible general availability of modern concentrates for the management of hemophilia A patients. Safety, cost and continuous supply of concentrates must be considered when deciding on a product for replacement therapy. As todays' products have reached an excellent margin of safety with regard to virus transmission, the development and treatment of inhibitors is currently the main concern for physicians and patients. The incidence of inhibitors is influenced by various patient-related factors such as mutation type or severity of the disease. Plasma-derived FVIII concentrates containing von Willebrand factor (VWF) may have clinical advantages over pure FVIII concentrates with regard to inhibitor development and inhibitor eradication. Clinical trials comparing FVIII/VWF concentrates with pure FVIII concentrates are lacking, thus a lower inhibitor incidence has not yet been proven. Data from Germany on immune tolerance induction with FVIII/VWF concentrates indicate higher success rates with these than with pure FVIII concentrates. In addition FVIII/VWF concentrates are the therapy of choice when immune tolerance therapy with pure FVIII products is not successful.     

Freiburg Intervention Trial for Obese Children (FITOC): results of a clinical observation study

BACKGROUND: The Freiburg Intervention Trial for Obese Children (FITOC) is an interdisciplinary, outpatient program for obese children consisting of regular physical exercise and comprehensive dietary and behavioral education. Parental involvement is required. The study is designed as a longitudinal, nonrandomized clinical observation study. An 8-month intensive phase preceded a follow-up phase of 1 y or longer. METHODS: Data were collected from 31 groups comprising 496 children (267 girls, 229 boys), with an average age of 10.5 y. Body height and weight, fasting total-cholesterol (CH), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and physical performance were measured initially and after 8.5 months. A group of n = 35 obese children (16 girls, 19 boys) who did not take part in this intervention program served as controls. RESULTS: After the intensive intervention phase, body mass index (BMI, kg/m2) as well as BMI deviation scores (BMI-SDS) decreased in both sexes (P<0.001). In the controls, BMI increased (P<0.001) and BMI-SDS remained constant. Whereas CH was only significantly lower (P<0.01) in boys after 8.5 months, LDL-C decreased significantly in both sexes. HDL-C tended to increase in both sexes (not significant). The controls showed no significant changes in CH, LDL-C and HDL-C. The fitness levels (W/kg body weight) improved in the intervention group (P<0.001), but not in the control group. CONCLUSIONS: The results indicate that obese children can be successfully treated in such an intervention program. BMI-SDS and risk factors decreased and physical performance improved. To maintain therapeutical success, we highly recommended that these children enroll in community-based exercise programs in order to help them maintain a more active lifestyle after the follow-up phase.     

Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and lack of tolerance

Summary Twenty patients with refractory heart failure NYHA class IV were randomly assigned to infusion therapy with 9.25 g/kg/min dobutamine over 24 hours or placebo. Eight infusions over a 4-week period were performed in the hospital; between infusions breaks of 3 days were scheduled. A dose titration was performed before study during which dobutamine was infused at 2.5 g/kg/min and increased by 2.5 g/kg/min steps every 15 minutes up to a maximum dosage of 10 g/kg/min. After dobutamine, exercise duration on the treadmill stress test increased from 177±110 seconds to 251 ±120 seconds (p<0.05). The heart-rate response to exercise increased (91±20 to 116±26 beats/min at baseline, 88±17 to 132±26 beats/min after therapy). Body weight decreased from 70.9±15.5 to 68.9±14.2 kg (p<0.03). On placebo, no significant changes were evident. Systolic time intervals and hemodynamic parameters showed only minor and not significant changes in both groups. No excess mortality emerged during intermittent dobutamine therapy. No clinical or hemodynamic signs of tolerance development were evident during control assessment 3 days after the last infusion. Intermittent therapy with dobutamine seems to be a promising concept in the management of refractory severe heart failure.